BiotechTube

TYRA-430

Phase 1Recruiting
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Metastatic Hepatocellular Carcinoma

Conditions

Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration, FGFR3 Gene Mutation, Advanced Solid Tumors, FGFR4 Gene Mutation, FGFR4 Gene Fusions, FGF19 Gene Amplification, FGF19 Gene Overexpression, FGFR3 Gene Fusions, Locally Advanced Unresectable Hepatocellular Carcinoma

Trial Timeline

Apr 24, 2025 → Sep 1, 2028

NCT ID
NCT06915753

About TYRA-430

TYRA-430 is a phase 1 stage product being developed by Tyra Biosciences for Metastatic Hepatocellular Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06915753. Target conditions include Metastatic Hepatocellular Carcinoma, Solid Tumors, Solid Tumor, Adult.

What happened to similar drugs?

20 of 20 similar drugs in Metastatic Hepatocellular Carcinoma were approved

Approved (20) Terminated (8) Active (0)
✅EnzalutamideAstellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅Enzalutamide + Androgen deprivation therapy (ADT)Astellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅Enfortumab VedotinAstellas PharmaApproved
✅EligardAstellas PharmaApproved
✅Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)Eli LillyApproved

Hype Score Breakdown

Clinical
6
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06915753Phase 1Recruiting

Competing Products

20 competing products in Metastatic Hepatocellular Carcinoma

See all competitors
ProductCompanyStageHype Score
CD40 agonist mitazalimab in combination with chemotherapyAlligator Bioscience ABPhase 1/2
26
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
18
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
35
SRF617 + etrumadenant + zimberelimabCoherus BioSciencesPhase 2
17
ZN-c3 + Encorafenib + CetuximabZentalis PharmaceuticalsPhase 1
11
AbemaciclibEli LillyPre-clinical
26
Ramucirumab + Placebo + Erlotinib + Gefitinib + OsimertinibEli LillyPhase 3
44
SYNB1891 + AtezolizumabSynlogicPhase 1
11
CT-P6 + Herceptin + PaclitaxelCelltrionPhase 3
40
CT-P6 + Herceptin + PaclitaxelCelltrionPhase 1/2
32
SPYK04Chugai PharmaceuticalPhase 1
33
LUNA18 + CetuximabChugai PharmaceuticalPhase 1
21
Induction therapyChugai PharmaceuticalPhase 2
42
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
40
Paclitaxel + Bevacizumab + Letrozole + Anastrozole + Exemestane + Fulvestrant + Goserelin + leuprorelinChugai PharmaceuticalPhase 2
35
bevacizumab + PaclitaxelChugai PharmaceuticalPhase 2
35
Bevacizumab + 5-fluorouracil + Leucovorin calcium + Irinotecan hydrochloride + Oxaliplatin + CapecitabineChugai PharmaceuticalPhase 2
31
GC33Chugai PharmaceuticalPhase 1
29
Gemcitabine and UFTE chemotherapyYuhanPhase 2
35
Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + PemetrexedDaiichi SankyoPhase 3
44